1. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis

   • Kui Li
   • Masaki Mandai
   • Ikuo Konishi

   Original Article 13 September 2008 Pages: 641 - 652

   

2. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice

   • Simona Vertuani
   • Chiara Triulzi
   • Rolf Kiessling

   Original Article 27 September 2008 Pages: 653 - 664

   

3. The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines

   • Rikke Bæk Sørensen
   • Niels Junker
   • Mads Hald Andersen

   Original Article 01 October 2008 Pages: 665 - 675

   

4. Enhancement of superantigen activity and antitumor response of staphylococcal enterotoxin C2 by site-directed mutagenesis

   • Xiaogang Wang
   • Mingkai Xu
   • Chenggang Zhang

   Original Article 26 September 2008 Pages: 677 - 686

   

5. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells

   • Yu Liu
   • Yinyan Yu
   • Rongcun Yang

   Original Article 01 October 2008 Pages: 687 - 697

   

6. Immunosensitization with a Bcl-2 small molecule inhibitor

   • Jonathan Begley
   • Dan D. Vo
   • Antoni Ribas

   Original Article 20 September 2008 Pages: 699 - 708

   

7. Characterization of MHC class-I restricted TCRαβ⁺ CD4⁻ CD8⁻ double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination

   • Simon Voelkl
   • Tamson V. Moore
   • Karin Fischer

   Original Article 03 October 2008 Pages: 709 - 718

   

8. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition

   • Tamson V. Moore
   • Gretchen E. Lyons
   • Michael I. Nishimura

   Original Article 03 October 2008 Pages: 719 - 728

   

9. Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines

   • Xuede Lin
   • Xiaojian Wang
   • Joyce C. Solheim

   Original Article 01 October 2008 Pages: 729 - 736

   

10. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts

    • Chih-Wen Tseng
    • Cornelia Trimble
    • T.-C. Wu

    Original Article 25 September 2008 Pages: 737 - 748

    

11. Paradoxical concentration effect of a homodimerizing antibody against a human non-small cell lung cancer cell line

    • Heinz Kohler
    • Ann Jay Bryan

    Original Article 27 September 2008 Pages: 749 - 758

    

12. Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity

    • Paula J. Whittington
    • Olga Radkevich-Brown
    • Wei-Zen Wei

    Original Article 03 October 2008 Pages: 759 - 767

    

13. Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth

    • Markus Loeffler
    • Gaelle Le’Negrate
    • John C. Reed

    Short Communication 17 July 2008 Pages: 769 - 775

    

14. Report on the sixth annual meeting of the Association for Immunotherapy of Cancer (CIMT), May 15 and 16, 2008 in Mainz, Germany

    • Marij J. P. Welters
    • Nadine van Montfoort
    • Cedrik M. Britten

    Meeting Report 04 November 2008 Pages: 777 - 787

15. Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines

    • Ann Mander
    • Ferdousi Chowdhury
    • Christian H. Ottensmeier

    Focussed Research Review 10 December 2008 Pages: 789 - 800

    

16. TNK cells (NKG2D⁺ CD8⁺ or CD4⁺ T lymphocytes) in the control of human tumors

    • Cristina Maccalli
    • Samantha Scaramuzza
    • Giorgio Parmiani

    Focussed Research Review 17 December 2008 Pages: 801 - 808

    

17. TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008

    • Wolfgang Uckert
    • Ton N. M. Schumacher

    Focussed Research Review 03 February 2009 Pages: 809 - 822

    

18. Ipilimumab: controversies in its development, utility and autoimmune adverse events

    • Jeffrey Weber

    Focussed Research Review 06 February 2009 Pages: 823 - 830